New findings could lead to better treatment for blood cancer
en-GBde-DEes-ESfr-FR

New findings could lead to better treatment for blood cancer


Which medicine is best when you are affected by cancer? This can vary from person to person. A new method can help people with a specific type of blood cancer get the best medicine for them.

“The new method can help those affected by chronic myelogenous leukemia,” says Jennifer Sheehan, a PhD research fellow from the Department of Mechanical Engineering and Production at NTNU. Sheehan was first author of a new publication in PLOS Computational Biology that describes the method.

The research is a collaboration between the Norwegian University of Science and Technology (NTNU), Linnaeus University in Sweden and the Universidade de São Paulo.

Blood cancer can develop insidiously

Chronic myelogenous leukemia, or CML, is a relatively rare variant of blood cancer. In Norway, around 70 people are affected per year.

The disease seems to be caused by a piece of one chromosome breaking off and attaching to another. This creates an abnormal gene that causes immature white blood cells to spread rapidly and fill the blood vessels. In other words, the patient gets cancer.

“CML is a form of cancer that many people live with for a long time without knowing it. Symptoms can be absent for several years before the patient becomes visibly ill,” says Astrid S. de Wijn, a professor at NTNU’s Department of Mechanical Engineering and Production, and Sheehan’s supervisor.

Finding the right medicine for CML

Today, the most effective form of treatment is stem cell transplantation. Many can avoid transplantation if they receive effective help with medication instead. The vast majority of people can manage without it, as long as they receive effective medications called thyrokinase inhibitors. But there are five different medications for CML, and it is important to find the one that is most effective.

The medications attack an enzyme. Enzymes are substances that are needed to start or keep various processes in the body going. The goal of the medications is to slow down the problematic overproduction of cells in the blood.

However, mutations, which are spontaneous changes in the cells, can cause the medications to lose all or part of their effect against blood cancer.

“We have developed a computer model that can help us say which drugs work best, and thus are best suited for each individual patient,” says Professor Ran Friedman at Linnaeus University.

J. Roadnight Sheehan, Astrid S. de Wijn, Thales Souza Freire, Ran Friedman. Beyond IC50—A computational dynamic model of drug resistance in enzyme inhibition treatment. Published: November 7, 2024. https://doi.org/10.1371/journal.pcbi.1012570
Regions: Europe, Norway, Sweden
Keywords: Health, Grants & new facilities, Medical, People in health research

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement